You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for CDDO Im
CDDO Im is an Nrf2 signaling activator; increases Nrf2 protein expression and enhances Nrf2-dependent cytoprotective gene expression. CDDO Im inhibits cell growth and induces apoptosis of pancreatic cancer cells in vitro. Also reduces acetaminophen-induced liver injury in mice.
Compound Libraries for CDDO Im
Technical Data for CDDO Im
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for CDDO Im
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for CDDO Im
The following data is based on the product molecular weight 541.72. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.85 mL||9.23 mL||18.46 mL|
|5 mM||0.37 mL||1.85 mL||3.69 mL|
|10 mM||0.18 mL||0.92 mL||1.85 mL|
|50 mM||0.04 mL||0.18 mL||0.37 mL|
References for CDDO Im
References are publications that support the biological activity of the product.
Reisman et al (2009) CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol.Appl.Pharmacol. 236 109 PMID: 19371629
Samudio et al (2005) 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J.Biol.Chem. 280 36273 PMID: 16118208
Aleksunes et al (2010) Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J.Pharmacol.Exp.Ther. 335 2 PMID: 20605904
If you know of a relevant reference for CDDO Im, please let us know.
View Related Products by Product Action
Keywords: CDDO Im, CDDO Im supplier, CDDOIm, Nrf2, activators, NFE2L2, erythroid-derived, nuclear, factor, 4737, Tocris Bioscience
4 Citations for CDDO Im
Citations are publications that use Tocris products. Selected citations for CDDO Im include:
Jörn et al (2018) Nrf2-Mediated Fibroblast Reprogramming Drives Cellular Senescence by Targeting the Matrisome. Dev Cell 46 145-161.e10 PMID: 30016619
Thomas W et al (2021) Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice. Kidney Int 99 102-116 PMID: 32818518
Chartoumpekis et al (2018) Nrf2 deletion from adipocytes, but not hepatocytes, potentiates systemic metabolic dysfunction after long-term high-fat diet-induced obesity in mice. Am J Physiol Endocrinol Metab 315 E180 PMID: 29486138
Kyung-Hyun et al (2020) NRF2 Is an Upstream Regulator of MYC-Mediated Osteoclastogenesis and Pathological Bone Erosion. Cells 9 PMID: 32967239
Do you know of a great paper that uses CDDO Im from Tocris? Please let us know.
Reviews for CDDO Im
There are currently no reviews for this product. Be the first to review CDDO Im and earn rewards!
Have you used CDDO Im?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Tricarboxylic Acid Cycle
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.